Cargando…

FZD10‐targeted α‐radioimmunotherapy with (225)Ac‐labeled OTSA101 achieves complete remission in a synovial sarcoma model

Synovial sarcomas are rare tumors arising in adolescents and young adults. The prognosis for advanced disease is poor, with an overall survival of 12‐18 months. Frizzled homolog 10 (FZD10) is overexpressed in most synovial sarcomas, making it a promising therapeutic target. The results of a phase 1...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sudo, Hitomi, Tsuji, Atsushi B., Sugyo, Aya, Harada, Yosuke, Nagayama, Satoshi, Katagiri, Toyomasa, Nakamura, Yusuke, Higashi, Tatsuya
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8819345/ https://www.ncbi.nlm.nih.gov/pubmed/34935247 http://dx.doi.org/10.1111/cas.15235

Ejemplares similares

Therapeutic efficacy evaluation of radioimmunotherapy with (90)Y‐labeled anti‐podoplanin antibody NZ‐12 for mesothelioma
por: Sudo, Hitomi, et al.
Publicado: (2019)

Preclinical Evaluation of Podoplanin-Targeted Alpha-Radioimmunotherapy with the Novel Antibody NZ-16 for Malignant Mesothelioma
por: Sudo, Hitomi, et al.
Publicado: (2021)

The natural sulfoglycolipid derivative SQAP improves the therapeutic efficacy of tissue factor-targeted radioimmunotherapy in the stroma-rich pancreatic cancer model BxPC-3
por: Takakusagi, Yoichi, et al.
Publicado: (2021)

α‐particle therapy for synovial sarcoma in the mouse using an astatine‐211‐labeled antibody against frizzled homolog 10
por: Li, Huizi Keiko, et al.
Publicado: (2018)

Combined treatment of pancreatic cancer xenograft with (90)Y-ITGA6B4-mediated radioimmunotherapy and PI3K/mTOR inhibitor
por: Aung, Winn, et al.
Publicado: (2017)

Treatment of Prostate Cancer with CD46-targeted (225)Ac Alpha Particle Radioimmunotherapy
por: Bidkar, Anil P., et al.
Publicado: (2023)

Efficacy Evaluation of Combination Treatment Using Gemcitabine and Radioimmunotherapy with (90)Y-Labeled Fully Human Anti-CD147 Monoclonal Antibody 059-053 in a BxPC-3 Xenograft Mouse Model of Refractory Pancreatic Cancer
por: Sugyo, Aya, et al.
Publicado: (2018)

Alpha radioimmunotherapy using (225)Ac-proteus-DOTA for solid tumors - safety at curative doses
por: Cheal, Sarah M., et al.
Publicado: (2020)

Evaluation of Efficacy of Radioimmunotherapy with (90)Y-Labeled Fully Human Anti-Transferrin Receptor Monoclonal Antibody in Pancreatic Cancer Mouse Models
por: Sugyo, Aya, et al.
Publicado: (2015)

Radioimmunotherapy of pancreatic cancer xenografts in nude mice using (90)Y-labeled anti-α(6)β(4) integrin antibody
por: Aung, Winn, et al.
Publicado: (2016)

Therapeutic Efficacy of C-Kit-Targeted Radioimmunotherapy Using 90Y-Labeled Anti-C-Kit Antibodies in a Mouse Model of Small Cell Lung Cancer
por: Yoshida, Chisato, et al.
Publicado: (2013)

Development of [(225)Ac]Ac-DOTA-C595 as radioimmunotherapy of pancreatic cancer: in vitro evaluation, dosimetric assessment and detector calibration
por: Hull, Ashleigh, et al.
Publicado: (2023)

Proof of Concept Study for Increasing Tenascin-C-Targeted Drug Delivery to Tumors Previously Subjected to Therapy: X-Irradiation Increases Tumor Uptake
por: Sugyo, Aya, et al.
Publicado: (2020)

[(225)Ac]Ac-SibuDAB for Targeted Alpha Therapy of Prostate Cancer: Preclinical Evaluation and Comparison with [(225)Ac]Ac-PSMA-617
por: Busslinger, Sarah D., et al.
Publicado: (2022)

Cyclotron production of (225)Ac from an electroplated (226)Ra target
por: Nagatsu, Kotaro, et al.
Publicado: (2021)

Synthesis and Stability of Actinium-225 Endohedral Fullerenes, (225)Ac@C(60)
por: Mwakisege, Jofa Gideon, et al.
Publicado: (2020)

Preclinical Evaluation of the Acute Radiotoxicity of the α-Emitting Molecular-Targeted Therapeutic Agent (211)At-MABG for the Treatment of Malignant Pheochromocytoma in Normal Mice
por: Sudo, Hitomi, et al.
Publicado: (2019)

Radiolabeled Human Monoclonal Antibody 067-213 has the Potential for Noninvasive Quantification of CD73 Expression
por: Sudo, Hitomi, et al.
Publicado: (2020)

Trastuzumab Conjugated Superparamagnetic Iron Oxide Nanoparticles Labeled with (225)Ac as a Perspective Tool for Combined α-Radioimmunotherapy and Magnetic Hyperthermia of HER2-Positive Breast Cancer
por: Cędrowska, Edyta, et al.
Publicado: (2020)

Resonant laser ionization and mass separation of $^{225}$Ac
por: Johnson, Jake D, et al.
Publicado: (2023)

Comparison of the biodistribution of $^{225}$Ac and radiolanthanides as citrate complexes
por: Beyer, Gerd-Jürgen, et al.
Publicado: (1990)

The application of poorly crystalline silicotitanate in production of (225)Ac
por: Fitzsimmons, Jonathan, et al.
Publicado: (2019)

Development of (225)Ac Radiopharmaceuticals: TRIUMF Perspectives and Experiences
por: Robertson, Andrew Kyle Henderson, et al.
Publicado: (2018)

Resonant laser ionization and mass separation of (225)Ac
por: Johnson, Jake D., et al.
Publicado: (2023)

Estimating (225)Ac yield in thorium metal targets
por: Rahmani, M., et al.
Publicado: (2023)

Evaluation of Actinium-225 Labeled Minigastrin Analogue [(225)Ac]Ac-DOTA-PP-F11N for Targeted Alpha Particle Therapy
por: Qin, Yun, et al.
Publicado: (2020)

In vivo validation of the switch antibody concept: SPECT/CT imaging of the anti-CD137 switch antibody Sta-MB shows high uptake in tumors but low uptake in normal organs in human CD137 knock-in mice
por: Sugyo, Aya, et al.
Publicado: (2022)

Cure of Disseminated Human Lymphoma with [(225)Ac]Ac-Ofatumumab in a Preclinical Model
por: Longtine, Mark S., et al.
Publicado: (2023)

A first-in-human study investigating biodistribution, safety and recommended dose of a new radiolabeled MAb targeting FZD10 in metastatic synovial sarcoma patients
por: Giraudet, Anne-Laure, et al.
Publicado: (2018)

Integrated treatment using intraperitoneal radioimmunotherapy and positron emission tomography-guided surgery with (64)Cu-labeled cetuximab to treat early- and late-phase peritoneal dissemination in human gastrointestinal cancer xenografts
por: Yoshii, Yukie, et al.
Publicado: (2018)

Nimotuzumab Site-Specifically Labeled with (89)Zr and (225)Ac Using SpyTag/SpyCatcher for PET Imaging and Alpha Particle Radioimmunotherapy of Epidermal Growth Factor Receptor Positive Cancers
por: Solomon, Viswas Raja, et al.
Publicado: (2020)

(111)In-labeled anti-cadherin17 antibody D2101 has potential as a noninvasive imaging probe for diagnosing gastric cancer and lymph-node metastasis
por: Fujiwara, Kentaro, et al.
Publicado: (2019)

Immunotargeting of Integrin α(6)β(4) for Single-Photon Emission Computed Tomography and Near-Infrared Fluorescence Imaging in a Pancreatic Cancer Model
por: Aung, Winn, et al.
Publicado: (2016)

Estimation of relative biological effectiveness of (225)Ac compared to (177)Lu during [(225)Ac]Ac-PSMA and [(177)Lu]Lu-PSMA radiopharmaceutical therapy using TOPAS/TOPAS-nBio/MEDRAS
por: Rumiantcev, Mikhail, et al.
Publicado: (2023)

New measurement of exotic decay of $^{225}$Ac by $^{14}$C emission
por: Guglielmetti, A, et al.
Publicado: (2001)

In Vitro Tumor Cell-Binding Assay to Select High-Binding Antibody and Predict Therapy Response for Personalized (64)Cu-Intraperitoneal Radioimmunotherapy against Peritoneal Dissemination of Pancreatic Cancer: A Feasibility Study
por: Hihara, Fukiko, et al.
Publicado: (2022)

Ac-EAZY! Towards GMP-Compliant Module Syntheses of (225)Ac-Labeled Peptides for Clinical Application
por: Pretze, Marc, et al.
Publicado: (2021)

Mycobacterial OtsA Structures Unveil Substrate Preference Mechanism and Allosteric Regulation by 2-Oxoglutarate and 2-Phosphoglycerate
por: Mendes, Vítor, et al.
Publicado: (2019)

In Vitro Evaluation of No-Carrier-Added Radiolabeled Cisplatin ([(189, 191)Pt]cisplatin) Emitting Auger Electrons
por: Obata, Honoka, et al.
Publicado: (2021)

Precise quantitative evaluation of pharmacokinetics of cisplatin using a radio-platinum tracer in tumor-bearing mice
por: Obata, Honoka, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_2ij25l1irf1f90kffonupijea7